The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression
Randomised, double-blind, placebo-controlled study (n=29 planned) assessing whether oral minocycline maintains antidepressant response after an open-label IV ketamine induction (0.5 mg/kg, six infusions) in patients with MDD and Bipolar II.
Details
This parallel, randomised, double-blind trial enrolled patients with moderate to severe major depressive disorder or Bipolar Disorder Type II who completed a 12-day open-label induction of six IV ketamine infusions (0.5 mg/kg) combined with minocycline.
Responders to the induction phase were randomised to oral minocycline 100 mg twice daily or matched placebo for up to 6 weeks to assess maintenance of antidepressant response; non-responders could receive open-label minocycline.
Primary efficacy assessed by MADRS; safety and tolerability monitored throughout with weekly visits until Day 54 or relapse.